MedTrace Logo

Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device

NCT01708213 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2014-12-17

Study results available
· View outcomes & findings →

Summary

The protocol hypothesis is that treatment with Aline HA™ will be safe through 6 months as determined by clinical assessment of treatment sites and routine tracking of adverse events.

Conditions

  • Disorder of Soft Tissue

Interventions

DEVICE

Aline HA

Implantable dermal filler

Sponsors & Collaborators

  • TauTona Group

    lead INDUSTRY

Principal Investigators

  • Nowell Solish, MD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2013-11-30
Completion
2013-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01708213 on ClinicalTrials.gov